Investment bank Berenberg has lowered its price target on Siemens Healthineers to €39 and assigned a hold rating, signaling that the medical-technology company faces more headwinds than catalysts in the near term. The downgrade reflects two main concerns: a prolonged timeline for the spin-off from parent Siemens AG and persistent weakness in the company's Diagnostics segment.
What Berenberg Sees
Berenberg's analysts argue that while Siemens Healthineers may appear cheap on some valuation metrics—such as an enterprise value-to-EBITDA multiple of roughly 11 times for the 2025/26 fiscal years—that low multiple alone does not guarantee a re-rating. The bank notes that the stock is weighed down by structural uncertainties that could keep it range-bound for the next year.
The first overhang is the spin-off from Siemens AG. Siemens announced plans to fully separate its healthcare unit, but the process is taking longer than many investors expected. Until the spin-off is completed, the market may remain cautious about the company's strategic direction and capital allocation.
The second issue is the Diagnostics division, which has been underperforming. Weakness in this segment—which provides laboratory diagnostics and point-of-care testing—has been a drag on overall results. Berenberg suggests that until Diagnostics shows a clear turnaround, the stock may struggle to gain momentum.
Context and Background
Siemens Healthineers is a global leader in medical imaging, laboratory diagnostics, and advanced therapies. It was carved out of the industrial conglomerate Siemens AG in 2017 and has since operated as a separately listed company, though Siemens AG still holds a majority stake. The planned full spin-off is intended to unlock value and give Healthineers more strategic independence.
The company's Diagnostics unit has faced headwinds from pricing pressure, supply chain disruptions, and slower-than-expected adoption of new products. In recent quarters, the division has weighed on overall revenue growth and profitability, making it a key focus for investors.
Berenberg's move is part of a broader reassessment of European healthcare stocks amid mixed economic signals and shifting interest rate expectations. Other analysts have also adjusted their views on the sector, with some raising targets on companies like Sartorius and Allianz based on different catalysts.
What It Means for Investors
For everyday investors, the downgrade is a reminder that a low valuation does not automatically make a stock a buy. Siemens Healthineers may look inexpensive on an earnings multiple basis, but the uncertainties around the spin-off and Diagnostics performance could keep the share price from rising in the near term.
Investors should watch for updates on the spin-off timeline and any signs of improvement in the Diagnostics business. If the company can resolve these two overhangs, the stock could become more attractive. But for now, Berenberg's hold rating suggests that the risk-reward balance is fairly neutral.
It is also worth noting that analyst price targets are not guarantees—they are estimates based on current information. The €39 target implies limited upside from recent trading levels, but the stock could move higher if conditions improve faster than expected.
For context, other European companies have faced similar analyst adjustments recently. For instance, Berenberg also sees Nordex's Q2 results slightly above consensus, while Munich Re's 2026 profit target remains achievable despite a revenue miss. These examples show that analyst views can vary widely across sectors and companies.
Ultimately, the Siemens Healthineers story is one of patience. The company has strong fundamentals in its core imaging and therapy businesses, but the path to a higher valuation may require clearing the two overhangs that Berenberg has highlighted.
